In this article, we will take a look at some of the best fast money stocks to buy now.

In this fast-paced world, most people have become impatient. Everyone is drawn to whatever delivers quick results, whether it be fast fame or fast money. When it comes to investing, some stocks are built for the long haul, while others return quickly.

That being said, investing in such stocks doesn’t necessarily imply jumping in the dark; instead, some stocks are designed in a way that drives returns through market volatility. From small-cap companies awaiting FDA approval or benefitting from successful trials to undervalued mid-caps, each is seeking its plot twist.

As stated in Morgan Stanley’s “Stocks’ Momentum Masks Risks,”

Consider that while the S&P 500 rose about 23% in 2024, the stocks with the strongest 12-month momentum (i.e., those rising the fastest for that time frame) were up an extraordinary 58% for the year, outperforming all other “factors,” including growth- and value-oriented equities, by at least 38 percentage points.

Our Methodology

Using Finviz’s stock screener, we have filtered for stocks trading under $50, exhibiting a relative volume of over 1.5 and a month-to-date performance of 50% or more as of September 28, 2025. These are then ranked in ascending order according to their upside potential, calculated using one-year price targets by Yahoo Finance.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

11. Dragonfly Energy Holdings Corp. (NASDAQ:DFLI)

Upside Potential as of September 29, 2025: 50.25%

On Friday, Wall Street Zen upgraded Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) to hold. This revision can be attributed to the company’s OEM collaboration with Ember Recreational Vehicles, which was announced on September 9, 2025. Under the contract, Ember’s 2026 Overland Series will feature Battle Born Batteries as part of the new Max Solar Package.

A testament to the many years-long partnership with Ember, the new standard Max Solar Package will enable Ember’s customers to benefit from a complete energy system for prolonged off-grid adventures, including 3.5 to 7 kWh of LiFePO₄ batteries and 1,200 watts of rooftop solar.

Developed to support a wide range of needs, the power system will include Battle Born GC3 deep-cycle batteries to enhance the overall experience. As stated by Wade Seaburg, Chief Commercial Officer of Dragonfly Energy Holdings Corp. (NASDAQ:DFLI),

By making Battle Born Batteries standard in the Overland Series, we believe Ember is giving its customers the energy storage capacity they need to take full advantage of their solar power. That means longer run times, the ability to power real appliances, and a more confident experience off the grid.

Dragonfly Energy Holdings Corp. (NASDAQ:DFLI), headquartered in Reno, Nevada, is a manufacturer and seller of deep-cycle lithium-ion batteries for vehicles, vessels, and industrial and energy storage markets. With a commitment to providing sustainable power solutions, the company operates through two segments: direct-to-consumers and original equipment manufacturers.

10. Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Upside Potential as of September 29, 2025: 57.35%

Clear Street assumed coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) with a ‘Buy’ rating and a price target of $100, implying a potential upside of nearly 172% from the current price. This optimism is driven by the company’s lead candidate, Claseprubart, which is what they refer to as a “best-in-class complement inhibitor.”

The research firm believes that Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is in a good position to enhance treatment standards in three autoimmune conditions undergoing clinical testing: generalized myasthenia gravis (gMG), chronic idiopathic demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN), with each of these representing a market of up to $2 billion.

While highlighting the company’s latest Phase 2 data in gMG, Clear Street noted the prospects surrounding CIDP and MMN, with data updates projected for the latter half of next year. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has already delivered a year-to-date return of 68.39%, outperforming the market average by an impressive 55.43%.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a New York-based clinical-stage biotechnology company offering solutions for patients living with severe autoimmune and inflammatory diseases. Founded in 2019, the company focuses on enhancing the selectivity of complement therapeutics.

9. PepGen Inc. (NASDAQ:PEPG)

Upside Potential as of September 29, 2025: 75.76%

H.C. Wainwright has reaffirmed its ‘Buy’ rating on PepGen Inc. (NASDAQ:PEPG), while increasing the price target to $12.00 from $8.00, implying a surge of nearly 135%. This optimism stems from the company’s 53.7% mean splicing correction at 15 mg/kg report in its FREEDOM single-dose study for DM1 patients, showcasing the highest level disclosed in DM1 patients till now.

The research firm noted that this nearly 54% splicing correction establishes a new standard, pointing to the high chances of repeat dosing delivering significant functional advancements. While expanding the therapeutic window for PepGen Inc. (NASDAQ:PEPG) to a safe and efficacious dose, this could return massively to real health improvements.

Considering the company’s financials, PepGen Inc. (NASDAQ:PEPG) delivered a return of 34.04% in contrast to the market’s average of 13.10%, reflecting an impressive outperformance of nearly 21%.

PepGen Inc. (NASDAQ:PEPG), headquartered in Boston, Massachusetts, is a clinical-stage biotechnology company specializing in oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Incepted in 2018, the company offers PGN-EDO51, PGN-EDODM1, and PGN-EDO53.